Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016

Date: 2016-05

“Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Estrogen Receptor Positive (ER+) Breast Cancer. The report provides the in-depth analysis of the pipeline assets across the Estrogen Receptor Positive (ER+) Breast Cancer. The Report gives insights on 40+ products. It also includes around 30+ companies which are active in this field. Estrogen Receptor Positive (ER+) Breast Cancer-Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Estrogen Receptor Positive (ER+) Breast Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Estrogen Receptor Positive (ER+) Breast Cancer.
These days’ companies are focusing on the Targeted Therapy for cancer. Ipsen’s Triptorelin pamoate is the Gonadotropin-releasing hormone (GnRH) Agonist in Phase III stage, Seattle Genetics’s SGN-LIV1A, is a monoclonal antibody in Phase I are competing against other small molecules. Many big pharmaceuticals companies are involved in ER Breast Cancer. Compared to other cancers, breast cancers show marked resistance to conventional forms of chemotherapy, and there are limited capabilities to diagnose and treat the disease in its earliest stages. No current treatment option has demonstrated long-term benefit in patients with advanced disease who are not eligible for surgery, which represents the majority (80%) of breast cancer cases. Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
• The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
• Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for ER Positive Breast Cancer and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample